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CapsuleAbstract In this work, a new isocratic reverse phase chromatographic method was developed using
HPLC for ziprasidone hydrochloride monohydrate (ZHM). The newly developed method is appli-
cable for assay determination of the ZHM in capsule dosage form. The chromatographic separation
of ZHM was achieved on a Zorbax SB C-8 (50 · 4.6) mm, 3.5 lm column within a short runtime of
2 min. The method was validated according to the International Conference on Harmonization
(ICH) guidelines with respect to speciﬁcity, precision, linearity, accuracy, range, stability of analyt-
ical solution, robustness and system suitability. The satisfying recoveries (98–100%) and low coef-
ﬁcient of variation conﬁrmed the suitability of the proposed method for the routine analysis of
ZHM in pharmaceuticals.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ziprasidone hydrochloride monohydrate (ZHM) is an antipsy-
chotic drug that chemically differs from phenothiazine or buty-
rophenone antipsychotic agents. ZHM is chemically known as
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one hydrochloride (Fig. 1) and is used for the
treatment of schizophrenia, mania and mixed states associated
with bipolar disorder. ZHM has a potent selective antagonist
activity for the serotonin type 2 (5-HT2), dopamine type 2
(D2), 1 and 2 adrenergic and H1 histaminergic receptors
(Brunton et al., 2006). Comprehensive literature survey reveals
that several analytical methods have been reported for the esti-
mation of ZHM, which include reverse phase high perfor-
mance liquid chromatography (RP-HPLC), high
performance thin layer chromatography (HPTLC), UV–visible
spectrophotometry and electrophoresis. Among them, most of
the analytical methods employed are aimed at quantifying
ZHM in biological ﬂuids using UV (Zhang et al., 2007a) and
ﬂuorescence (Suckow et al., 2004) detection as well as
LCMS/MS (Zhang et al., 2007b) method. Other methods re-
Figure 1 Structure of ZHM.
S162 R. Bansal et al.ported to determine ZHM in bulk and its pharmaceutical dos-
age forms includes RP-HPLC (Rani and Reddy, 2006; Prasan-
thi and Rao, 2010; Chudasama et al., 2010; Palvovic et al.,
2011), normal and reverse phase HPTLC (Skibin´ski and Kom-
sta, 2010), capillary zone electrophoresis (Farina et al., 2008),
UV-spectrophotometry (Jain et al., 2006; Kumar et al., 2010)
and visible-spectrophotometric (Srinubabu et al., 2006; Kishore
and Hanumantharao, 2010) methods. All the methods reported
in the literatures have longer run time. The utilization of higher
sample throughput with more information per sample will de-
crease the time to market and is an important driving force in
today’s pharmaceutical industry. The target of this study is to
develop a new, simple, rapid, economical, precise and accurate
analytical method by RP-HPLC to quantify ZHM in capsule
dosage forms together with its validation study. This work de-
scribes the validation parameters stated by the International
Conference on Harmonization (ICH) guidelines which include
speciﬁcity, precision, linearity, accuracy, range, stability of ana-
lytical solution, robustness and system suitability.
2. Experimental
2.1. Chemicals and reagents
A reference standard of ZHM (Potency: 96.0%w/w on as is ba-
sis) and its impurities were synthesized in Jubilant Life Sciences
Limited, Nanjangud, India and characterized by using LC–MS,
IR and NMR. ZHM capsules were purchased from local phar-
macy. The HPLC grade solvents used were of E-Merck (India)
Ltd., Mumbai. Potassium dihydrogen orthophosphate, trieth-
ylamine, hydrochloric acid, ortho phosphoric acid, sodium
hydroxide, methanol, acetonitrile, hydrogen peroxide, (Merck,
Mumbai, India) were used in the analysis. HPLC grade water
was prepared using Millipore puriﬁcation system.
2.2. Instrumentation
AHPLC instrument (Waters Acquity separations module) con-
sisting of Photodiode Array Detector (ACQ-PDA) equipped
with Empower Chromatographic Software at wavelength
229 nmwas used for this analysis. The chromatographic separa-
tions were performed on aZorbax SBC-8 (50 · 4.6) mm, 3.5 lm
column by keeping it on 40 Cusing a ﬂow rate of 0.9 mL min1
with the run time of 2 min. Injection volume was set as 1 lL.
2.3. Mobile phase and diluent
The mobile phase was a mixture of buffer (pH = 3.0) and
methanol (45:55 v/v), ﬁltered through 0.2 lm ﬁner porosity ny-lon membrane ﬁlter and degassed prior to use. The buffer
(pH = 3.0) was prepared by dissolving about 1.36 g of
potassium dihydrogen ortho phosphate and 2 mL of triethyl-
amine in 1000 mL of water and adjusting the pH to
3.0 ± 0.05 with ortho phosphoric acid. Water and acetonitrile
in the ratio of 30:70 was used as diluent.
2.4. Standard preparations
Standard stock solution was prepared by dissolving ZHM
standard equivalent to 100 mg of ZHM in 50 mL of diluent.
The above stock solution was diluted to get a ﬁnal standard
concentration of 200 lg ml1.
2.5. Sample solution
The sample solution was prepared by taking the content of ﬁve
capsules (ZHM capsules, 40 mg cap1 strength) into 250 mL
volumetric ﬂask and dissolved in 75 mL of water then soni-
cated to disintegrate the capsules. Further the solution was di-
luted with 100 mL of acetonitrile, subsequently sonicated for
about 45 min with intermittent shaking. Allowed to cool to
room temperature and made up the volume with acetonitrile.
A portion of the solution was centrifuged for about 5 min at
4000 rpm, followed that 5 mL of supernatant solution was di-
luted to 20 mL with diluent. Then the solution was ﬁltered
through 0.2 lm nylon membrane ﬁlter.
2.6. Validation
The developedmethod has been validated for the assay of ZHM
in capsules, 40 mg cap1, strength using following parameters
(CPMP/ICH/281/95, 1994; CPMP/ICH/381/95, 1996; Sethi,
1996; Gennaro, 2000; Kazakevich and Lobrutto, 2007).
2.6.1. System suitability
200 lg mL1 concentration of ZHM standard was prepared
and injected into the chromatography as six replicates. The
tailing factor for the ZHM peak from the ﬁrst injection of
the standard preparation should be less than 2.0, and the col-
umn efﬁciency determined from ZHM peak from the ﬁrst
injection of the standard preparation should not be less than
1500 theoretical plates. The relative standard deviation for
the mean area calculated for ZHM peak from the six replicate
injections of standard preparation should be less than 2.0%.
2.6.2. Speciﬁcity
Speciﬁcity is the ability of the method to measure the analyte
response in the presence of its potential impurities. Speciﬁcity
consisted of interference and forced degradation studies.
2.6.3. Interference study
Sample and placebo solutions of ZHM capsules were prepared
and analyzed to check the peak purity of ZHM peak in sample
solution. Further, the sample solution of ZHM capsules was
spiked with ZHM hydrochloride related substances (Impurity
A, Impurity B, Impurity C, Impurity D and open ring) at
about 1% level, in triplicate, to check its interference, if any,
with ZHM peak. Peak purity was calculated from the ZHM
peak in the spiked sample solution. Speciﬁcity of the method
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unspiked and spiked samples.
2.6.4. Precision
In precision study; system precision, method precision and
intermediate precision have been carried out. The system pre-
cision was examined by analyzing standard solution in six rep-
licates. %RSD of area counts of ZHM peak was calculated. In
method precision, six preparations of a single batch of ZHM
capsules, 40 mg cap1 against ZHM standard solution were
examined. Intermediate precision (Ruggedness) was repeated
using different analysts, on different days, on different instru-
ments and using column of different lot. Overall RSD for as-
say between the two sets of data was calculated.
2.6.5. Linearity
From the standard stock solution, a series of solutions were pre-
pared at concentration levels ranging from 20% to 299% of
standard concentration. The peak area responses of solutions
at all levels in duplicateweremeasured.Thepeak response verses
concentration data was treated by linear regression analysis and
the linearity of response for ZHMwas determined by calculating
correlation coefﬁcient (acceptance criterion: correlation coefﬁ-
cient shall not be less than 0.999).
2.6.6. Accuracy
For accuracy study, known amount of placebo was taken sep-
arately into different volumetric ﬂasks and spiked with known
quantities of ZHM active pharmaceutical ingredient at three
different levels, in triplicate. Accuracy has been performed at
about 29.1% (Level 1), 98.7% (Level 2) and 198.3% (Level
3) of sample concentration. The samples were analyzed by
the proposed method and the amount of ZHM recovered
was calculated (acceptance criterion: %Recovery shall be in
the range of 98–102. Individual and overall %RSD of %recov-
ery shall not be more than 2.0).
2.6.7. Stability of analytical solution
Standard and sample solutions of ZHM capsules, 40 mg cap1,
were prepared and kept at 25 C. Both the solutions were ana-
lyzed initially and at different time intervals. Cumulative
%RSD of area counts for the standard solution and assay
(%claim) for the sample solution was calculated. In standard
solution, cumulative %RSD of area counts up to 1671 min at
25 C was calculated. In sample solution, cumulative %RSD
of assay (%claim) up to 1616 min at 25 Cwas calculated (accep-
tance criterion: cumulative %RSD shall not be more than 2.0).
2.6.8. Robustness
Robustness of the method was investigated by varying the
instrumental conditions such as wavelength of detection
(±5 nm), column oven temperature (±5 C), minor compo-
nent in mobile phase (±2% absolute), ﬂow rate (±10%) and
pH of Buffer (±0.2 unit). System suitability of the standard
solution was checked at each variable condition. The theoreti-
cal plates, tailing factor of ZHM peak from standard solution
and %RSD of area counts of standard solution for each set
of data were calculated. Sample solution of ZHM capsules,
40 mg cap1, was prepared in triplicate and analyzed under
each condition and %claim of ZHM was calculated. Robust-ness of the method was indicated by the overall %RSD between
the data of method precision and data at each variable condi-
tion (acceptance criterion: System suitability should pass and
overall %RSD of %Assay shall not be more than 2.0).
2.7. Forced degradation
ZHM was deliberately subjected to stress to establish the sta-
bility-indicating nature of the method. The compound was ex-
posed to light (in a photolytic chamber at about 1.2 million lux
hours and 200 W h/m2), heat (105 C for 168 h), acid (5.0 N
HCl – 5 mL/70 C/120 min), alkali (0.1 N NaOH – 5 mL/
70 C/30 min), oxidation (3.0% H2O2 – 5 mL/70 C/30 min),
and humidity (95% RH for 168 h) to evaluate the ability of
the method to separate ZHM from its degradation products.
Peak purity was determined using PDA detector.3. Results and discussion
3.1. HPLC method development and optimization
The chromatographic method was optimized by changing var-
ious parameters, such as the mobile phase composition and pH
of the buffer used in the mobile phase. Retention time and sep-
aration of peak of ZHM were dependent on the pH of the buf-
fer and the percentage of methanol. Different mobile phases
were tried, but satisfactory separation and good symmetrical
peak were obtained with the mobile phase consisting of buffer
(pH = 3.0) and methanol in the ratio of 45:55% v/v with Zor-
bax SB C-8 (50 · 4.6) mm, 3.5 lm column within a short run-
time of 2 min. The column selection and shorter run time
depicts the cost effectiveness of the method. A typical chro-
matogram obtained by using the aforementioned mobile phase
and 1 lL of the injected assay preparation is illustrated in
Fig. 2. Retention time for ZHM was found to be 1.2 min.
No blank peak interference at the retention time of known
peak was obtained as shown in Fig. 3.3.2. System suitability
Standard solution was injected on different days during the
validation study. Using the system suitability software, theo-
retical plates and tailing factor for ZHM peak were calculated.
Also, %RSD for six replicate injections was calculated. The
tailing factor for the ZHM standard peak from the ﬁrst injec-
tion of the standard preparation was 1.06, theoretical plates
for ZHM peak from standard solution was 3453 and the rela-
tive standard deviation for the mean area calculated for ZHM
peak from the six replicate injections of standard preparation
was 0.44%. The above three system suitability parameters
were met during the course of entire validation.3.3. Speciﬁcity
The result of interference study indicates that there are no co-
eluting peaks from placebo as well as no interference of ZHM
known impurities with ZHM peak as the purity plot indicates
that the ZHM peak is homogeneous. The purity angle is less
than purity threshold for the ZHM peak in the unspiked and
Figure 2 Chromatogram of ZHM (control sample).
Figure 3 Peak purity of ZHM (control sample).
Figure 4 Chromatogram of Placebo solution (no interference at the retention time of ZHM).
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%difference of 0.39 between mean assay of unspiked (102.5%)and spiked samples (102.9%), so this method is selective and
speciﬁc (Figs. 2–5 demonstrate the speciﬁcity of the method).
Figure 5 Peak purity of ZHM (spiked sample).
Table 1 Results of forced degradation study.
Mode of degradation Condition Assay
(% claim)
%Degradation
w.r.t. control
Purity
angle
Purity
threshold
Control No treatment 102.5 – 0.052 0.278
Acid degradation 5 N
HCl
5 mL/70 C/120 min/
neutralized
94.3 8 0.057 0.268
Alkali degradation 0.1 N
NaOH
5 mL/70 C/30 min/
neutralized
94.2 8 0.056 0.262
Peroxide degradation 3%
w/v H2O2
5 mL/70 C/30 min 101.0 1 0.055 0.263
Thermal degradation 105 C/168 h 97.9 4 0.056 0.264
Photolytic degradation 1.2 million lux hours and
200 W h/m2
101.0 1 0.056 0.264
Humidity degradation 95% RH/168 h 99.0 3 0.060 0.266
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when ZHM exposed to acid and alkali hydrolysis, thermal and
humidity. Minor degradation was observed when sample ex-
posed to peroxide and photolytic conditions. Results from peak
purity testing conﬁrmed the main compound peak obtained by
analysis of all the stress samples was homogenous and pure
and unaffected by the presence of its degradation products, con-
ﬁrming the stability indicating nature of themethod. The results
from forced degradation studies are summarized in Table 1.
3.4. Precision
The HPLC system has an acceptable level of precision as the
acceptance criterion for individual and overall %RSD should
not be more than 2.0 for precision, which was achieved suc-
cessfully. The system is found to be precise as the %RSD of
the area counts for six injections of the standard solution
was 0.44. The method is also precise as the %RSD of amount
present for ZHM in the sample was 0.59. In intermediate pre-
cision, individual %RSD of amount present for ZHM was
found to be 0.59 for Set I (method precision data), 1.40 for
Set II and overall %RSD value of 1.03 between the two sets
of data and hence the method is found to be rugged (Table 2).3.5. Linearity
The regression equation from peak response verses concentra-
tion data obtained y= 3830.9x  14190 and correlation coef-
ﬁcient was 0.999 indicating that the response is linear over the
speciﬁed range.
3.6. Accuracy
The recovery of three sample preparation at each level was
examined and ranged from 98.65% to 99.03%. As %recovery
is found within the acceptance criteria, also individual and
overall %RSD of %recovery is found within the acceptance
criteria, the method is accurate. Results are summarized in
Table 3.
3.7. Range
From the data of precision, linearity and accuracy, it is con-
cluded that the method validated in the range of
58.21 lg mL1 and 396.63 lg mL1 (29.1–198.3%) of standard
concentration is signiﬁcant.
Table 2 Data for precision.
System precision Method precision Intermediate precision
Injection no. Area counts (lV s) Sample no. Assay (% claim) Sample no. Assay(%claim)
Set-I Set-II
1 747992 1 102.3 1 102.3 100.1
2 744290 2 102.0 2 102.0 104.1
3 745800 3 103.0 3 103.0 101.4
4 753856 4 101.9 4 101.9 103.1
5 747779 5 103.4 5 103.4 102.3
6 748308 6 102.2 6 102.2 101.5
Mean 748004 Mean 102.5 Mean 102.5 102.1
SD 3257.0 SD 0.60 SD 0.6 1.4
%RSD 0.44 %RSD 0.59 %RSD 0.59 1.4
Overall mean 102.3
Overall SD 1.05
Overall %RSD 1.03
Table 4 Robustness data.
Method parameters System suitability of standard solution Assay (% claim) of
ziprasidone
%RSD Overall
%RSD
Theoretical plates Tailing factor %RSD
Control (method precision) 3453 1.06 0.49 102.5 0.59 –
Variation in wavelength (224 nm) 3367 1.06 0.39 101.4 0.55 0.76
Variation in wavelength (234 nm) 3392 1.07 0.38 101.3 0.58 0.80
Variation in column oven temperature (35 C) 3297 1.10 0.24 100.6 0.90 1.11
Variation in column oven temperature (45 C) 3214 1.09 0.29 101.3 0.45 0.77
Variation in minor component of mobile phase (2% absolute) 3475 1.08 0.47 101.2 0.29 0.80
Variation in minor component of mobile phase (+2% absolute) 3572 1.07 0.27 101.1 1.40 1.07
Variation in ﬂow rate (0.81 mL/min) 3598 1.10 0.81 101.4 0.63 0.75
Variation in ﬂow rate (0.99 mL/min) 3214 1.09 0.29 101.5 0.29 0.69
Variation in pH of buﬀer solution (pH 2.80) 3602 1.09 0.52 102.6 0.39 0.51
Variation in pH of buﬀer solution (pH 3.20) 3356 1.05 0.32 101.8 0.30 0.60
Table 3 Accuracy result.
Recovery levels Conc. (lg/mL) Amount added (mg) Amount recovered (mg) %Recovery Mean SD %RSD
Level 1 58.21 58.21 57.53 98.83 98.65 0.452 0.46
58.10 58.10 57.02 98.14
58.22 58.22 57.63 98.99
Level 2 197.43 197.43 195.01 98.77 98.69 0.381 0.39
197.55 197.55 195.63 99.03
197.62 197.62 194.22 98.28
Level 3 396.55 396.55 390.34 98.43 99.03 0.565 0.57
396.61 396.61 393.13 99.12
396.63 396.63 394.83 99.55
Overall 98.79 0.447 0.45
S166 R. Bansal et al.3.8. Stability of analytical solution
In standard solution, cumulative %RSD of area counts up to
1671 min at 25 C is 0.69%. In sample solution, cumulative
%RSD of assay (%claim) up to 1616 min at 25 C is 0.46%.
As the cumulative %RSD of standard solution and sample
solution of ZHM capsules, 40 mg cap1, is within theacceptable limits (less than 2.0%), it reveals that standard
and sample are stable in solution for at least 26 h at 25 C.
3.9. Robustness
In all the deliberate varied chromatographic conditions (wave-
length of detection, column oven temperature, minor compo-
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obtained were well within the limit. The validation data have
been incorporated in Table 4 which proves the robustness of
the method.
4. Conclusion
The present HPLC method for the determination of assay of
ZHM in capsule dosage form is simple, rapid, economical, pre-
cise and accurate. The method has been validated and satisfac-
tory results were observed for all the tested validation
parameters. All the previously published methods have longer
run times, in this method run time was 2 min, it saves time for
analysis, reduces mobile phase consumption and allows scien-
tist to release results report on time as more than 200 samples
can be done in one working day using this method. Hence, the
developed method can be conveniently used for determining
the quality control of ZHM in bulk pharmaceuticals. More-
over, the lower solvent consumption along with the short ana-
lytical run time of 2.0 min leads to cost effective
chromatographic method.
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